FULL PAPER

New Pyrano-4H-benzo[g]chromene-5,10-diones with Antiparasitic and Antioxidant Activities

Ibrahim S. Al Nasr,[a, b] Jana Jentzsch,[c] Amin Shaikh,[d] Priti Singh Shuveksh,[d] Waleed S. Koko,[b] Tariq A. Khan,[e] Khursheed Ahmed,[d] Rainer Schobert,[f] Klaus Ersfeld,[c] and Bernhard Biersack*[f]

[a] Department of Biology, College of Science and Arts, Qassim University, Unaizah 51911, Saudi Arabia
[b] Department of Science Laboratories, College of Science and Arts, Qassim University, Ar Rass 51921, Saudi Arabia
[c] Laboratory of Molecular Parasitology, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany
[d] Department of Chemistry, Abeda Inamdar Senior College, 2390-B, K.B. Hidayatullah Road, Pune 411001, India
[e] Department of Clinical Nutrition, College of Health Sciences, Qassim University, Ar Rass 51921, Saudi Arabia
[f] Organic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany,
e-mail: bernhard.biersack@yahoo.com

New pyranonaphthoquinone derivatives were synthesized and investigated for their activity against *Trypanosoma brucei*, *Leishmania major*, and *Toxoplasma gondii* parasites. The pentafluorophenyl derivative was efficacious against *T. brucei* with single digit micromolar EC_{50} values and against *T. gondii* with even sub-micromolar values. The 3-chloro-4,5-dimethoxyphenyl derivative showed an activity against amastigotes of *Leishmania major* parasites comparable to that of amphotericin B. In addition, antioxidant activities were observed for the bromophenyl derivatives, and their redox behavior was studied by cyclovoltammetry. Anti-parasitic and antioxidative activities of the new naphthoquinone derivatives appear uncorrelated.

Keywords: lawsone, neglected tropical diseases, pyran, biological activity.

Introduction

Infections of immune-compromised patients and new-born children with the world-wide occurring toxoplasmosis (caused by *Toxoplasma gondii* parasites) can lead to severe complications and, thus, efficient drugs for the treatment of toxoplasmosis are necessary.[1] In addition, neglected tropical diseases (NTDs) pose an eminent danger to people living or working in affected territories.[2,3] Human African trypanosomiasis (HAT, sleeping sickness) and leishmaniasis are NTDs which can ultimately lead to death of untreated patients. *Trypanosoma brucei gambiense* (*T. b. gambiense*, in West and Central Africa) and *T. b. rhodesiense* (in East Africa) are the two prevalent forms of trypanosomes which are responsible for sleeping sickness in humans while the Nagana disease of cattle (animal trypanosomiasis) is mainly caused by *T. b. brucei*.[4,5] The diamidine pentamidine and the urea derivative suramin are drugs only applicable for patients with early stage sleeping sickness, late stages were treated with highly toxic arsenics such as melarsoprol for a long time.[6] Meanwhile, the less toxic ornithine derivative eflornithine in combination with the nitrofuran nifurtimox (nifurtimox-eflornithine combination treatment, NECT) has replaced melarsoprol for the treatment of late stage *T. b. gambiense* infections (g-HAT).[6] The nitroimidazole fexinidazole was the first orally active drug which is applied for the treatment of stage 1 and stage 2 g-HAT.[5] The benzoxaborole derivative acozi-borole is currently tested in phase 2/3 clinical trials with stage 2 g-HAT patients.[5] Leishmaniasis is

Supporting information for this article is available on the WWW under https://doi.org/10.1002/cbdv.202000839

clinically subdivided into the cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL) forms, which show different clinical outcomes. VL is caused by *Leishmania infantum* (*L. infantum*) and *L. donovani* protozoal parasites and eventually leads to death resulting into a severe medical problem in regions where VL is endemic, e.g., in South Asia, Africa, Latin America and the Mediterranean region.[7] The liposomal formulation of the natural polyene macrolide amphotericin B (AmBisome) and combinations of AmBisome with the phospholipid miltefosine are currently applied for the treatment of VL.[7] The skin damaging CL form, which is caused by various *Leishmania* species such as *L. major*, *L. tropica*, *L. mexicana*, *L. amazonensis* etc., is the most widespread form of leishmaniasis diseases with 0.7 – 1 million predominantly young patients every year.[8,9] Although CL is usually not lethal, it causes severe and disfiguring skin lesions and affected persons are often stigmatized.[10,11] Current treatment options for CL patients include pentavalent antimonials (sodium stibogluconate, meglumine antimoniate), miltefosine, amphotericin, and pentamidine. Recent works disclosed interesting preclinical results for benzoxaborole, nitroimidazoles and aminopyrazoles as well as for the antimonial drug activity enhancer D35 (a CpG oligonucleotide).[9,12] Aside of the toxicity of the currently applied drugs, the emergence of drug-resistant parasite forms poses a growing problem to the clinician and, thus, the search for new potent antiparasitic drugs is ongoing. The treatment of trypanosomiasis and leishmaniasis with natural products or with drugs derived from them appears promising.[3,13] Naphthoquinones represent a significant group of secondary metabolites of plants and lichens with a variety of biological activities such as antioxidant and trypanocidal activities.[3,13–15] The natural 2-hydroxy-1,4-naphthoquinone (lawsone, **1a**) isolated from the Henna plant *Lawsonia inermis* showed biological activities including antibacterial effects and was applied as starting material for quinone drug candidates such as lapachol and atovaquone (ATO).[3,13–16] Modified lawsone derivatives with antitumor and antifungal activities are also known.[3,17,18] Quite a few lawsone derivatives were found efficacious against various parasites including *Plasmodium falciparum*, *Leishmania donovani*, *Trypanosoma cruzi* and *Toxoplasma gondii*.[3,19–23] Our own previous works have led to the identification of lawsone Mannich bases and naphthoquinone derivatives (**1b**–**1d**) with reasonable activities against *Trypanosoma brucei*, *Entamoeba histolytica*, *L. major* or *T. gondii* (*Figure 1*).[3,24,25] The fusion of the lawsone scaffold with heterocyclic rings such as pyrans can be another promising method in order to obtain new active compounds based on lawsone and various anti-tumor active derivatives as well as tumor cell senescence-inducing complexes were already identified (**1e**).[26,27] In continuation of these previous reports, we present new lawsone-derived pyranonaphthoquinone derivatives and their antioxidant and antiparasitic activities against *T. bruce*i, *L. major* and *T. gondii*.

Results and Discussion

Compounds **2a**–**2o** were prepared by Knoevenagel reaction of malononitrile and the respective aryl aldehyde under basic conditions followed by Michael addition of lawsone (**1a**) and ring-closure to the pyran ring in a multi-component one-pot reaction


Figure 1. Lawsone (**1a**), selected anti-parasitic derivatives (**1b**–**1d**), and anti-tumor active pyran (**1e**).

	R	Yield [%]		R	Yield [%]
2a	3-Br-4,5-(MeO)$_2$–C$_6$H$_2$	56	**2i**	3,4-Cl$_2$–C$_6$H$_3$	34
2b	3-Cl-4,5-(MeO)$_2$–C$_6$H$_2$	47	**2j**	4-MeS–C$_6$H$_4$	75
2c	3,5-Br$_2$-4-MeO–C$_6$H$_2$	50	**2k**	3-F-4-MeS–C$_6$H$_3$	61
2d	2-F–C$_6$H$_4$	60	**2l**	3-SF$_5$–C$_6$H$_4$	41
2e	3,4-F$_2$–C$_6$H$_3$	42	**2m**	3-CN–C$_6$H$_4$	31
2f	3,5-F$_2$–C$_6$H$_3$	45	**2n**	4-CN–C$_6$H$_4$	45
2g	2,4,5-F$_3$–C$_6$H$_2$	31	**2o**	4-HC≡C–C$_6$H$_4$	32
2h	2,3,4,5,6-F$_5$–C$_6$	31			

Scheme 1. Synthesis of compounds **2a**–**2o**.

(*Scheme 1*).[25,26] Compounds **2a**–**2o** were obtained as yellow, brown or red-orange solids in moderate yields.

The compounds **2a**–**2o** were tested against *T. gondii* parasites and their activities were compared with those against non-malignant Vero cells (*Table 1*). Except for **2a** and **2c**, all test compounds exhibited distinct activity against *T. gondii*. Compound **2h** showed the highest activity in the sub-micromolar range (EC$_{50}$ = 0.7 μM) and a reasonable selectivity (SI = 19.1). Compounds **2g** and **2o** showed similar selectivities (SI = 19.6 for **2g**, 22.1 for **2o**). Considerably higher selectivities were observed for **2d** (SI = 34.5), **2f** (SI =

Table 1. Antitoxoplasmal activity of compounds **2a**–**2o** as EC$_{50}$ (effective concentration that causes 50% inhibition for *T. gondi* in μM)[a], while IC$_{50}$ is the inhibition concentration for 50% of the Vero (African green monkey kidney epithelial in μM). ATO was used as positive control.

Compound	EC$_{50}$ (*T. gondii*)	IC$_{50}$ (Vero)	SI (Vero/*T. gondii*)[b]
2a	131 ± 13	4.1 ± 0.6	0.03
2b	1.7 ± 0.2	0.7 ± 0.08	0.43
2c	10.6 ± 1.7	6.0 ± 0.72	0.57
2d	1.7 ± 0.18	59.8 ± 7.4	34.5
2e	2.5 ± 0.3	17.1 ± 2.3	6.92
2f	2.2 ± 0.25	76.6 ± 8.7	34.9
2g	1.8 ± 0.22	35.8 ± 4.4	19.6
2h	0.7 ± 0.1	13.7 ± 1.5	19.1
2i	2.8 ± 0.32	17.4 ± 2.4	6.26
2j	4.5 ± 0.46	45.1 ± 6.2	9.94
2k	3.1 ± 0.38	30.3 ± 3.9	9.92
2l	1.3 ± 0.5	54.6 ± 6.2	41.4
2m	1.4 ± 0.42	9.1 ± 1.4	6.44
2n	1.4 ± 0.53	17.9 ± 2.1	12.64
2o	2.8 ± 0.35	62.7 ± 6.0	22.1
ATO	0.07 ± 0.004	9.5 ± 1.54	136
Doxorubicin	–	0.4 ± 0.01[c]	–

[a] Values are the average of three repeated reading for each test ± SE. Which were obtained from concentration-response curves by measuring the percentage of vital cells relative to untreated group after 3 days of incubation. [b] Selectivity index (SI) calculated by dividing IC$_{50}$ over EC$_{50}$ of the corresponding values. [c] Value is taken from ref. 28.

34.9), and **2l** (SI = 41.4). Although the selectivity of these compounds is lower when compared with the selectivity of the approved drug ATO, they were less toxic than ATO against Vero cells and, thus, they can be less toxic alternatives to ATO treatment.

Next, compounds **2a**–**2o** were investigated against *L. major* promastigotes and amastigotes and their activities were compared with those against non-malignant Vero cells (*Table 2*). Compound **2b** showed excellent activity against *L. major* amastigotes (EC$_{50}$ = < 0.5 μM) and, thus, **2b** was at least comparably active when compared with the approved drug amphotericin B (AmB) in this regard. However, **2b** was also quite toxic to Vero cells (i.e., it was almost as toxic as doxorubicin) leading to a relatively low selectivity when compared with AmB.[28] In addition, compounds **2a**, **2e**, **2h**, **2i**, and **2m** showed activities against the amastigotes with EC$_{50}$ values below 10 μM. Compounds **2d** (SI = 4.22) and **2o** (SI = 5.26) revealed the highest selectivities for *L. major* amastigotes. Compound **2h** also showed moderate activity against *L. major* promastigotes (EC$_{50}$ = 15.3 μM). However, the activity of the test compounds **2a**–**2o** against promastigotes was distinctly lower when compared with their activities against amastigotes.

Selected compounds were also tested against *T. b. brucei* (*Table 3*). Pentamidine served as positive control here.[29] Compound **2h** showed the highest activities against the *T. b. brucei* cells followed by **2f** and **2a**. The highest selectivity was observed for **2f** (SI = 12.8). Compounds **2b**, **2c**, and **2m** were inactive at doses up to 10 μM.

The antioxidant activities of selected compounds **2a**–**2f**, **2h**, **2m** and **2n** were evaluated using the 1,1-diphenyl-2-picrylhydrazil (DPPH) assay (*Table 4*). The radical derivative DPPH is a radical scavenger and functions as a trap for other radicals and, thus, it is the functional compound of common antioxidant assays.[30–32] Compounds **2a** and **2c** showed distinctly higher antioxidant activities when compared with the other test compounds. Both compounds were also

Table 2. Antileishmanial activity of compounds **2a**–**2o** as EC_{50} (effective concentration that causes 50% inhibition for *L. major* amastigotes and promastigotes in μM)[a], AmB was used as positive control.

Compound	EC_{50} promastigotes	EC_{50} amastigotes	SI Vero/promastigotes[b]	SI Vero/amastigotes[b]
2a	49.2 ± 5.2	8.4 ± 1.1	0.08	0.49
2b	34.1 ± 4.4	< 0.5	0.02	> 1.5
2c	22.3 ± 3.1	35.8 ± 4.3	0.27	0.17
2d	146 ± 16.5	14.2 ± 1.6	0.41	4.22
2e	37.9 ± 4.7	7.4 ± 0.9	0.45	2.31
2f	86.5 ± 9.1	31.3 ± 3.4	0.89	2.45
2g	25.6 ± 3.6	11.3 ± 0.9	1.40	3.19
2h	15.3 ± 1.9	5.7 ± 0.8	0.89	2.38
2i	35.8 ± 4.0	9.8 ± 1.1	0.49	1.77
2j	98.0 ± 10.1	34.2 ± 4.7	0.46	1.32
2k	46.4 ± 5.2	24.5 ± 3.9	0.65	1.24
2 l	84.1 ± 9.3	22.2 ± 2.8	0.65	2.46
2m	29.4 ± 3.6	7.9 ± 1.0	0.31	1.15
2n	37.9 ± 4.5	26.6 ± 2.6	0.47	0.67
2o	41.2 ± 5.0	11.9 ± 2.1	1.52	5.26
AmB	0.83 ± 0.09	0.47 ± 0.06	9.6	16.4

[a] Values are the average of three repeated reading for each test $\pm$ SE. Which were obtained from concentration-response curves by measuring the percentage of vital cells relative to untreated group after 3 days of incubation. [b] Selectivity index (SI) calculated by dividing IC_{50} (from *Table 1*) over EC_{50} of the corresponding values.

Table 3. Antitrypanosomal activity of compounds **2a**–**2c**, **2f**, **2h** and **2m** as EC_{50} (effective concentration that causes 50% inhibition for *T. b. brucei* in μM)[a], pentamidine was used as positive control.

Compound	IC_{50} (*T. b. brucei*)	SI Vero/*T. b. brucei*[b]
2a	7.6	0.54
2b	> 10	–
2c	> 10	–
2f	6.0	12.8
2h	4.9	2.8
2m	> 10	–
Pentamidine	0.000042[c]	–

[a] Values are the means of at least three independent experiments (SD $\pm$ 15%). They were derived from concentration–response curves obtained by measuring the percentage of vital cells relative to untreated controls after 72 h. [b] Selectivity index calculated from the corresponding IC_{50} values for the Vero cells and the IC_{50} values for *T. b. brucei*. [c] Value is taken from ref. [29].

Table 4. Inhibitory concentrations IC_{50} of ascorbic acid (positive control) and test compounds **2a**–**2f**, **2h**, **2m**, and **2n** when tested for their antioxidant activities (DPPH assay).

Compound	IC_{50} [μM]
Ascorbic acid	20
2a	3.75
2b	22
2c	2.25
2d	28
2e	16
2f	21
2h	25
2m	20
2n	30

more active than the known antioxidant ascorbic acid. There seems to be no or just a marginal correlation between antioxidant activity and anti-parasitic activity of the test compounds.

The cell-independent redox properties of lawsone derivatives **2a** to **2o** were studied by cyclic voltammetry (*Figure S1–S7*). **2a** gave rise to a pair of peaks at -358 mV (i_{pa} -0.889 μA) and -556 mV (i_{pc} 1.792 μA) indicative of a three-electron transfer redox couple with $E_{1/2} = -457$ mV. While **2c** and **2h** showed similar

redox couples with almost the same $\triangle E$ values, these compounds displayed another irreversible cathodic peak between -1004 mV and 1050 mV with different current values (i_{pc} 0.3104 μA in case of **2c**). Such a redox behavior was reported for other lawsone derivatives and the redox couple at $E_{1/2} = -457$ mV can be assigned to the conversion of naphthoquinone (NQ) to naphthosemiquinone (NSQ) (NQNSQ), while the irreversible peak at 1050 mV can be assigned to the following $2e^-$ reduction to the catechol form (NSQ→CAT).[33–35] The shift of this redox couple towards a more negative potential when compared to the parent lawsone compound can be attributed to the changes occurring in the electron density based

on the bromine atoms of **2a** and **2c**. The electron distributions in redox active ligands were correlated with a preferential reduction of certain ligands.[36–38] The π-orbital of the benzosemiquinone-type radical ligand of **2c** having a large overlap area might contribute to its greater ROS producing effects and, thus, showed the highest antioxidant activity compared to the other test compounds. In case of **2d**, a large gain in the current (i_{pc} 1.3047 μA and i_{pa} −1.4905 μA) was probably due to the electron withdrawing effects of the fluorine atom and, thus, a fast electron transfer was facilitated (*Figure S1*).[36] Compound **2h** showed a redox couple at $E_{1/2} = -428.5$ mV with high current values (i_{pc} 1.9638 μA and i_{pa} −1.0944 μA).

Conclusions

New lawsone-derived compounds were identified as anti-parasitic and antioxidant agents. The high anti-parasitic activities of **2h** against *T. brucei* and *T. gondii* warrant a further investigation of its effects on these parasites and other protozoal parasites such as *Plasmodium* species. The highest antioxidant activities, i.e., the strongest suppression of radical formation, were observed for compounds **2a** and **2c**, which showed relatively weak activities in the anti-parasitic assays (except for **2a** against *T. brucei*) and so there is apparently no strong correlation between antioxidant and anti-parasitic activities of the test compounds.

Experimental Section

General

Starting materials and pure solvents were purchased from common providers and used without further purification. IR spectra were measured on a PerkinElmer Spectrum One FT-IR spectrophotometer equipped with an ART sampling unit. NMR spectra were measured on a Bruker Avance 300 spectrometer and chemical shifts (δ) are given in parts per million (ppm) downfield from Me$_4$Si as internal standard. Coupling constants (J) are given in Hz. Mass spectra were measured on a Varian MAT 311A (EI). Elemental analyses were carried out with a Perkin–Elmer 2400 CHN elemental analyzer.[3]

2-Amino-4-(3-bromo-4,5-dimethoxyphenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2a**). 3-Bromo-4,5-dimeth-

oxybenzaldehyde (245 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added, and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 262 mg (0.56 mmol, 56%). Orange solid. M.p. 250–251 °C. IR: 3392, 3319, 3256, 3222, 3201, 3017, 2989, 2940, 2825, 2201, 1666, 1655, 1637, 1607, 1591, 1567, 1488, 1460, 1442, 1403, 1363, 1316, 1302, 1278, 1241, 1226, 1206, 1177, 1136, 1077, 1037, 1001, 949, 866, 819, 769, 747, 732, 721, 712, 680. ¹H-NMR (300 MHz, (D$_6$)DMSO): 3.70 (3 H, s), 3.81 (3 H, s), 4.61 (1 H, s), 7.01 (1 H, s), 7.11 (1 H, s), 7.36 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ¹³C-NMR (75.5 MHz, (D$_6$)DMSO): 36.2, 56.2, 57.1, 60.0, 112.2, 116.7, 119.3, 120.8, 123.1, 125.8, 126.0, 130.8, 131.1, 134.1, 134.4, 141.2, 144.6, 149.3, 153.3, 158.3, 176.8, 182.7; EI-MS: 468 (100) [M⁺], 466 (97) [M⁺], 437 (11), 435 (11), 387 (72), 251 (92). Anal. calc. for C$_{22}$H$_{15}$BrN$_2$O$_5$ (467.28): C 56.55, H 3.24, N 6.00; found: C 56.41, H 3.16, N 5.88.

2-Amino-4-(3-chloro-4,5-dimethoxyphenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2b**). 3-Chloro-4,5-dimethoxybenzaldehyde (200 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added, and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with H$_2$O/MeCN and dried in vacuum. Yield: 200 mg (0.47 mmol, 47%). Orange solid. M.p. 306–307 °C. IR: 3393, 3323, 3256, 3222, 3200, 2991, 2941, 2827, 2202, 1668, 1655, 1638, 1592, 1572, 1492, 1448, 1428, 1417, 1404, 1364, 1341, 1331, 1318, 1303, 1282, 1242, 1228, 1207, 1179, 1161, 1094, 1079, 1046, 1028, 1001, 949, 868, 851, 844, 818, 7973 784, 771, 752, 733, 722, 697, 682, 631, 602; ¹H-NMR (300 MHz, (D$_6$)DMSO): 3.71 (3 H, s), 3.81 (3 H, s), 4.62 (1 H, s), 6.9–7.0 (2 H, m), 7.35 /2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ¹³C-NMR (75.5 MHz, (D$_6$)DMSO)) 36.2, 56.2, 57.1, 60.1, 111.5, 119.2, 120.4, 120.7, 125.8, 126.0, 126.8, 130.8, 131.0, 134.1, 134.4, 140.6, 143.6, 149.3, 153.4, 158.3, 176.8, 182.6; EI-MS: 424 (34) [M⁺], 422 (100) [M⁺], 387 (63), 251 (77). Anal. calc. for C$_{22}$H$_{15}$ClN$_2$O$_5$ (422.82): C 62.50, H 3.58, N 6.63; found: C 62.29, H 3.46, N 6.46.

2-Amino-4-(3,5-dibromo-4-methoxyphenyl)-5,10-dihydro-5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (**2c**). 3,5-Dibromo-4-methoxybenzaldehyde (293 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et₃N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 260 mg (0.50 mmol, 50%). Orange-red solid. M.p. 267 °C. IR: 3414, 3323, 3281, 3253, 3211, 3194, 2201, 1658, 1638, 1606, 1594, 1547, 1471, 1417, 1401, 1362, 1334, 1300, 1262, 1203, 1183, 1100, 1074, 1040, 1025, 991, 948, 800, 782, 733, 717, 695, 668; ^{1}H-NMR (300 MHz, CDCl₃/(D₆)DMSO)): 3.74 (3 H, s), 4.60 (1 H, s), 6.85 (2 H, s), 7.40 (2 H, s), 7.7–7.8 (2 H, m), 7.9–8.0 (1 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, CDCl₃/(D₆)DMSO)): 35.3, 56.8, 59.9, 117.6, 118.4, 121.5, 125.9, 126.0, 129.9, 130.7, 131.7, 133.6, 134.2, 140.9, 148.1, 152.6, 158.6, 176.4, 181.9. EI-MS: 518 (40) [M⁺], 516 (72) [M⁺], 514 (40) [M⁺], 437 (16), 435 (15), 251 (100). Anal. calc. for $C_{21}H_{12}Br_2N_2O_4$ (516.15): C 48.87, H 2.34, N 5.43; found: C 48.69, H 2.24, N 5.30.

2-Amino-4-(2-fluorophenyl)-5,10-dihydro-5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (**2d**). 2-Fluorobenzaldehyde (124 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et₃N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 90 min. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 207 mg (0.60 mmol, 60%). Orange solid. M.p. 250–251 °C. IR: 3401, 3318, 3253, 3215, 3190, 2197, 1685, 1664, 1634, 1601, 1579, 1488, 1453, 1407, 1364, 1328, 1303, 1247, 1227, 1207, 1174, 1150, 1098, 1076, 1025, 951, 845, 779, 756, 745, 714, 671. ^{1}H-NMR (300 MHz, (D₆)DMSO)): 4.91 (1 H, s), 7.1–7.5 (6 H, m), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D₆)DMSO)): 30.4, 56.0, 115.3–115.6 (m), 119.1, 120.9, 124.8, 125.8, 126.1, 129.1–129.2 (m), 130.2–130.9 (m), 134.2–134.6 (m), 149.5, 158.0, 159.7 (d, J = 246 Hz), 176.8, 182.5. EI-MS: 346 (100) [M⁺], 302 (6), 251 (87), 223 (7), 173 (7), 105 (5), 76 (5). Anal. calc. for $C_{20}H_{11}FN_2O_3$ (346.32): C 69.36, H 3.20, N 8.09; found: C 69.44, H 3.12, N 7.96.

2-Amino-4-(3,4-difluorophenyl)-5,10-dihydro-5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (**2e**). 3,4-Difluorobenzaldehyde (142 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et₃N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 151 mg (0.42 mmol, 42%). Orange solid. M.p. 260 °C. IR: 3403, 3331, 3290, 3256, 3195, 3073, 2206, 1664, 1656, 1639, 1620, 1606, 1594, 1581, 1517, 1438, 1412, 1363, 1332, 1302, 1284, 1274, 1244, 1204, 1179, 1153, 1117, 1096, 1076, 1039, 1021, 972, 950, 933, 900, 882, 865, 838, 820, 799, 790, 772, 763, 752, 730, 713, 673. ^{1}H-NMR (300 MHz, (D₆)DMSO)): 4.67 (1 H, s), 7.2–7.5 (5 H, m), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D₆)DMSO)): 35.8, 56.9, 116.6–117.5 (m), 119.1, 120.7, 124.6, 125.8, 126.0, 130.7, 131.0, 134.1, 134.5, 141.4–141.5 (m), 146.8–147.8 (m), 149.3, 150.0–151.1 (m), 158.2, 176.8, 182.6. EI-MS: 364 (100) [M⁺], 320 (6), 251 (91), 223 (8). Anal. calc. for $C_{20}H_{10}F_2N_2O_3$ (364.31): C 65.94, H 2.77, N 7.69; found: C 66.02, H 2.61, N 7.80.

2-Amino-4-(3,5-difluorophenyl)-5,10-dihydro-5,10-dioxo-4H-naphtho[2,3-b]pyran-3-carbonitrile (**2f**). 3,5-Difluorobenzaldehyde (142 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et₃N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 165 mg (0.45 mmol, 45%). Orange-red solid. M.p. 270 °C. IR: 3395, 3315, 3249, 3211, 3190, 3090, 2200, 1663, 1622, 1594, 1580, 1463, 1449, 1404, 1363, 1338, 1311, 1303, 1290, 1242, 1206, 1178, 1124, 1077, 1040, 1026, 1005, 991, 963, 944, 863, 838, 817, 772, 737, 728, 710, 682, 674. ^{1}H-NMR (300 MHz, (D₆)DMSO)): 4.70 (1 H, s), 7.0–7.2 (3 H, m), 7.41 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D₆)DMSO)): 36.2, 56.6, 102.2–102.9 (m), 110.8–111.1 (m), 119.0, 120.2, 125.8, 126.0, 130.8, 131.0, 134.1, 134.4, 148.1–148.3 (m), 149.6, 158.3, 162.4 (dd, J = 13.1 Hz, 247 Hz), 176.7, 182.6. EI-MS: 364 (96) [M⁺], 251 (100). Anal. calc. for $C_{20}H_{10}F_2N_2O_3$ (364.31): C 65.94, H 2.77, N 7.69; found: C 66.00, H 2.63, N 7.78.

2-Amino-5,10-dihydro-5,10-dioxo-4-(2,4,5-tri-fluorophenyl)-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2g**). 2,4,5-Trifluorobenzaldehyde (160 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (3 mL) and five drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. Lawsone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 30 min. The formed precipitate was collected, washed with MeCN and dried in vacuum. Yield: 120 mg (0.31 mmol, 31%); Orange solid. M.p. 274–275 °C. IR: 3411, 3318, 3220, 3194, 3059, 2208, 1660, 1640, 1626, 1606, 1593, 1515, 1427, 1412, 1369, 1332, 1316, 1302, 1266, 1245, 1208, 1185, 1158, 1142, 1094, 1070, 1019, 950, 899, 874, 846, 816, 761, 741, 715, 670, 620. ^{1}H-NMR (300 MHz, CDCl$_3$/(D$_6$)DMSO)): 4.85 (1 H, s), 6.46 (2 H, s), 6.8–6.9 (1 H, m), 7.0–7.1 (1 H, m), 7.6–7.7 (2 H, m), 7.8–7.9 (1 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, CDCl$_3$/(D$_6$)DMSO) δ 30.7, 56.4, 105.1–105.7 (m), 117.1–117.4 (m), 118.0, 120.5, 125.9, 126.0, 129.9, 130.6, 133.5, 134.1, 148.5, 158.5, 176.3, 181.8. EI-MS: 382 (100) [M$^+$], 251 (92). Anal. calc. for C$_{20}$H$_9$F$_3$N$_2$O$_3$ (382.30): C 62.84, H 2.37, N 7.33; found: C 62.75, H 2.29, N 7.24.

2-Amino-5,10-dihydro-5,10-dioxo-4-(2,3,4,5,6-pentafluorophenyl)-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2h**). Pentafluorobenzaldehyde (196 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (3 mL) and five drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. Lawsone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 30 min. The formed precipitate was collected, washed with MeCN and dried in vacuum. Yield: 131 mg (0.31 mmol, 31%). Orange solid. M.p. 281–282 °C. IR: 3427, 3286, 3174, 2202, 1669, 1635, 1520, 1505, 1412, 1366, 1330, 1302, 1247, 1207, 1154, 1118, 1079, 1041, 1024, 992, 954, 937, 824, 790, 768, 719, 704, 648, 610. ^{1}H-NMR (300 MHz, (D$_6$)DMSO) δ 5.13 (1 H, s), 7.66 (2 H, s), 7.8–8.0 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO) δ 26.8, 52.6, 115.8, 118.7–118.9 (m), 125.9, 126.2, 129.7, 130.4, 130.9, 135.3, 138.4, 143.0, 146.4, 149.3, 159.5, 176.6, 182.2. EI-MS: 418 (100) [M$^+$], 251 (75). Anal. calc. for C$_{20}$H$_7$F$_5$N$_2$O$_3$ (418.28): C 57.43, H 1.69, N 6.70; found: C 57.30, H 1.62, N 6.61.

2-Amino-4-(3,4-dichlorophenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2i**). 3,4-Dichlorobenzaldehyde (175 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in

MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 135 mg (0.34 mmol, 34%). Orange-red solid. M.p. 283–285 °C. IR: 3396, 3328, 3196, 2203, 1658, 1638, 1605, 1593, 1471, 1411, 1362, 1333, 1294, 1243, 1207, 1177, 1157, 1127, 1093, 1079, 1029, 1017, 973, 948, 872, 834, 822, 793, 772, 750, 738, 728, 715, 682, 659, 617, 583. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 4.69 (1 H, s), 7.36 (1 H, dd, J=8.8 Hz, 2.2 Hz), 7.40 (2 H, s), 7.64 (1 H, dd, J=8.3 Hz, 2.4 Hz), 7.42 (2 H, s), 7.57 (1 H, d, J=8.3 Hz), 7.64 (1 H, d, J=2.4 Hz), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO): 35.8, 56.7, 119.1, 120.4, 125.8, 126.0, 128.3, 129.7, 129.8, 130.6, 130.8, 131.0, 131.1, 134.1, 134.5, 144.8, 149.4, 158.3, 176.8, 182.6. EI-MS: 398 (15) [M$^+$], 396 (23) [M$^+$], 251 (61), 57 (100). Anal. calc. for C$_{20}$H$_{10}$Cl$_2$N$_2$O$_3$ (397.21): C 60.48, H 2.54, N 7.05; found: C 60.32, H 2.48, N 7.11.

2-Amino-5,10-dihydro-4-[4-(methylthio)phenyl]-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2j**). 4-Methylsulfanylbenzaldehyde (152 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. The formed precipitate was dissolved by heating the reaction mixture and 2-hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 280 mg (0.75 mmol, 75%). Orange-red solid. M.p. 266 °C. IR: 3398, 3319, 3248, 3211, 2194, 1691, 1655, 1638, 1604, 1593, 1494, 1409, 1365, 1336, 1303, 1238, 1208, 1179, 1162, 1097, 1077, 1041, 1026, 986, 986, 956, 945, 846, 833, 800, 771, 741, 720, 686. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 2.43 (3 H, s), 4.58 (1 H, s), 7.19 (2 H, d, J=8.6 Hz), 7.26 (2 H, d, J=8.6 Hz), 7.33 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 14.6, 36.0, 57.3, 119.3, 121.8, 125.8, 126.1, 128.3, 130.6, 131.0, 134.1, 134.5, 148.8, 158.3, 176.9, 182.6. EI-MS: 374 (100) [M$^+$], 327 (45), 251 (69). Anal. calc. for C$_{21}$H$_{14}$N$_2$O$_3$S (374.41): C 67.37, H 3.77, N 7.48; found: C 67.22, H 3.66, N 7.37.

2-Amino-4-[3-fluoro-4-(methylthio)phenyl]-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2k**). 3-Fluoro-4-methylsulfanylbenzaldehyde

(170 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 240 mg (0.61 mmol, 61%). Orange-red solid. M.p. 244–245 °C. IR: 3402, 3320, 3251, 3212, 3071, 3046, 2937, 2896, 2195, 1691, 1663, 1665, 1639, 1603, 1593, 1563, 1481, 1412, 1363, 1336, 1300, 1279, 1238, 1207, 1179, 1153, 1096, 1065, 1040, 1026, 954, 931, 881, 838, 822, 803, 776, 761, 736, 719, 695, 685, 619, 561, 553. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 2.45 (3 H, s), 4.64 (1 H, s), 7.1–7.3 (3 H, m), 7.36 (2 H, s), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 14.0, 35.8, 57.0, 114.2–114.5 (m), 119.1, 120.9, 123.7, 124.0, 124.4, 125.8, 126.0, 127.5, 130.7, 131.0, 134.1, 134.4, 142.9, 149.2, 158.3, 158.9 (d, J = 242 Hz), 176.8, 182.6. EI-MS: 392 (100) [M$^+$], 345 (28), 251 (82). Anal. calc. for C$_{21}$H$_{13}$FN$_2$O$_3$S (392.40): C 64.28, H 3.34, N 7.14; found: C 64.09, H 3.26, N 7.05.

2-Amino-5,10-dihydro-5,10-dioxo-4-[3-(pentafluoro-λ^6-sulfanyl)phenyl]-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2 l**).
3-Pentafluorothiobenzaldehyde (232 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (5 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 16 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 185 mg (0.41 mmol, 41%). Orange-red solid. M.p. 283 °C. IR: 3413, 3340, 3256, 3222, 3194, 3076, 2201, 1656, 1637, 1591, 1484, 1435, 1412, 1361, 1336, 1300, 1252, 1243, 1203, 1185, 1161, 1112, 1095, 1072, 1022, 945, 881, 839, 823, 805, 793, 780, 731, 718, 699, 687, 678. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 4.84 (1 H, s), 7.43 (2 H, s), 7.5–7.6 (1 H, m), 7.6–7.7 (1 H, m), 7.7–7.9 (5 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 36.5, 56.8, 119.0, 120.5, 124.5, 125.0, 125.8, 126.1, 129.9, 130.7, 131.0, 131.9, 134.2, 145.4, 149.5, 152.9, 158.3, 176.8, 182.6. EI-MS: 454 (100) [M$^+$], 326 (51), 251 (100). Anal. calc. for C$_{20}$H$_{11}$F$_5$N$_2$O$_3$S (454.37): C 52.87, H 2.44, N 6.17; found: C 52.72, H 2.34, N 6.11.

2-Amino-4-(3-cyanophenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2m**).
3-Cyanobenzaldehyde (131 mg, 1.0 mmol) and malo-nonitrile (70 mg, 1.0 mmol) were dissolved in MeCN (3 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 110 mg (0.31 mmol, 31%). Red solid. M.p. 257 °C. IR: 3425, 3329, 3284, 3256, 3222, 3190, 2235, 2201, 1668, 1656, 1637, 1602, 1589, 1484, 1411, 1370, 1336, 1301, 1243, 1195, 1180, 1160, 1140, 1091, 1074, 7036, 1022, 955, 928, 815, 774, 756, 727, 716, 696. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 4.73 (1 H, s), 7.41 (2 H, s), 7.5–7.6 (1 H, m), 7.7–7.8 (2 H, m), 7.8–7.9 (4 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 36.2, 56.8, 111.6, 118.7, 119.1, 120.4, 125.8, 126.0, 129.7, 130.8, 130.9, 131.4, 132.8, 134.1, 134.5, 145.3, 149.6, 158.3, 176.8, 182.6. EI-MS: 353 (94) [M$^+$], 251 (100). Anal. calc. for C$_{21}$H$_{11}$N$_3$O$_3$ (353.34): C 71.39, H 3.14, N 11.89; found: C 71.31, H 3.22, N 11.78.

2-Amino-4-(4-cyanophenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2n**).
4-Cyanobenzaldehyde (131 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (3 mL) and three drops of Et$_3$N were added. The reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 160 mg (0.45 mmol, 45%). Red solid. M.p. 279–280 °C. IR: 3402, 3322, 3284, 3249, 3218, 3194, 2231, 2203, 1675, 1662, 1639, 1602, 1505, 1411, 1363, 1340, 1331, 1303, 1244, 1203, 1178, 1159, 1095, 1074, 1037, 1020, 949, 842, 797, 777, 752, 740, 721, 679. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 4.74 (1 H, s), 7.44 (2 H, s), 7.56 (2 H, dd, J = 8.4 Hz, 1.8 Hz), 7.78 (2 H, dd, J = 8.4 Hz, 1.8 Hz), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 36.6, 56.5, 109.9, 118.7, 119.0, 120.7, 125.8, 126.1, 128.9, 130.7, 130.9, 132.6, 134.2, 134.5, 149.0, 149.5, 158.4, 176.7, 182.5. EI-MS: 353 (95) [M$^+$], 251 (100). Anal. calc. for C$_{21}$H$_{11}$N$_3$O$_3$ (353.34): C 71.39, H 3.14, N 11.89; found: C 71.29, H 3.20, N 11.81.

2-Amino-4-(4-ethynylphenyl)-5,10-dihydro-5,10-dioxo-4*H*-naphtho[2,3-*b*]pyran-3-carbonitrile (**2o**).
4-Ethynylbenzaldehyde (130 mg, 1.0 mmol) and malononitrile (70 mg, 1.0 mmol) were dissolved in MeCN (3 mL) and three drops of Et$_3$N were added. The

reaction mixture was stirred at room temperature for 30 min. 2-Hydroxy-1,4-naphthoquinone (174 mg, 1.0 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The formed precipitate was collected, washed with MeCN and *n*-hexane and dried in vacuum. Yield: 114 mg (0.32 mmol, 32%). Orange-red solid. M.p. $>395\,°C$. IR: 3401, 3322, 3296, 3215, 2193, 1693, 1662, 1639, 1601, 1593, 1529, 1505, 1414, 1365, 1336, 1301, 1241, 1208, 1182, 1161, 1095, 1073, 1042, 1018, 963, 947, 849, 799, 779, 755, 744, 720, 693. ^{1}H-NMR (300 MHz, (D$_6$)DMSO)): 4.14 (1 H, s), 4.64 (1 H, s), 7.3–7.4 (6 H, m), 7.8–7.9 (3 H, m), 8.0–8.1 (1 H, m). ^{13}C-NMR (75.5 MHz, (D$_6$)DMSO)): 57.0, 80.8, 83.2, 119.2, 120.5, 121.4, 125.8, 126.1, 128.1, 130.7, 131.0, 131.9, 134.2, 134.5, 144.5, 149.1, 158.4, 176.8, 182.6. EI-MS: 352 (100) [M$^+$], 251 (81). Anal. calc. for C$_{22}$H$_{12}$N$_2$O$_3$ (352.35): C 74.99, H 3.43, N 7.95; found: C 75.10, H 3.31, N 7.82.

Toxoplasma gondii *Cell Line, Culture Conditions and Assay*

Vero cells (ATCC® CCL81™, USA) were applied for the cultivation of *T. gondii* tachyzoites of the RH strain. The Vero cells in 96-Well plates were cultured in RPMI 1640 medium (5×10^3 cells/well in 200 μL) with 10% heat inactivated fetal bovine serum (FBS, Invitrogen, USA) in a humidified 5% CO$_2$ atmosphere at $37\,°C$. The inhibition assay with the *T. gondii* parasites in Vero cells was carried out as described previously.[25,39]

Leishmania major *Cell Isolation and Culture Conditions*

Promastigotes of *L. major* were isolated in February 2016 and maintained in Schneider's Drosophila medium (Invitrogen, USA), which was supplemented with 10% FBS and antibiotics, in a tissue culture flask with weekly transfers at $26\,°C$. Promastigotes were cryopreserved in liquid nitrogen at concentrations of 3×10^6 parasite/mL. The virulence of *L. major* parasites was maintained by passing in female BALB/c mice via injection of 1×10^6 stationary-phase promastigotes in the hind footpads. *L. major* amastigotes were isolated from the treated mice after 8 weeks. The transformation of the isolated amastigotes into promastigotes was achieved by culturing at $26\,°C$ in Schneider's medium supplemented with 10% FBS and antibiotics. Amastigote-derived promastigotes with less than five *in vitro* passages were used for the infection of mice. Male and female BALB/c mice were obtained from Pharmaceutical College, King Saud University, Saudi Arabia, and maintained in specific pathogen-free facilities.[40,41] Concerning the mentioned laboratory animals, we followed all the instructions and rules designed by the Scientific Research Deanship, Qassim University, Saudi Arabia, under the permission/accreditation number 10124-cosao-2020-1-3-l.

Leishmania major *Cell Assays*

Cell assays with *L. major* promastigotes and amastigotes were carried out as described previously.[41–48]

Trypanosoma *Cell Line and Culture Conditions*

Cultivation of the *T. b. brucei* bloodstream form cell strain Lister 427 was carried out in HMI-9 medium, pH 7.5, supplemented with 10% FBS at $37\,°C$ in a humidified 5% CO$_2$ atmosphere.[3,42]

Alamar Blue (AB) Assay

Viable cells after treatment with drug candidates were identified via the AB assay.[42–45] Pink resorufin is formed in intact cells from the irreversible reaction of the blue dye resazurin and NADH. *T. b. brucei* cells (8000/well) were seeded on 96-well microplates, test compounds (dissolved in DMSO) were added and the cells were incubated for 72 h (5% CO$_2$, 95% humidity, $37\,°C$). AB reagent (10 μL of 500 μM resazurin sodium salt in PBS) was added and the cells were incubated for additional 4 h at $37\,°C$. Fluorescence (extinction at 544 nm, emission at 590 nm) was determined on an Omega FLUOstar (BMG Labtech) fluorescence plate reader. The IC$_{50}$ values were determined with the Quest Graph™ IC$_{50}$ Calculator (AAT Bioquest Inc.).[47]

In Vitro *Cytotoxicity Assay*

MTT assay with Vero cells was carried out for cytotoxicity evaluation of compounds. The assay was carried out as reported previously.[47,48]

Antioxidant Assay

Aliquots of eight concentrations (1, 5, 10, 20, 25, 50, 100, and 150 μM) of test compounds dissolved in methanol were added to eight test tubes. Compounds were accurately dissolved in methanol to achieve the required concentrations by dilution techniques. 5 mL of 0.004% 1,1-diphenyl-2-picrylhydrazil (DPPH) solution was given to each test tube using a micropipette. The solutions were kept at room temperature for 30 minutes to complete the reaction. DPPH was added

to a blank test tube containing only methanol. After 30 min the absorbance was measured with a double beam spectrophotometer (JASCO V-630) at 517 nm. IC_{50} values were calculated from the plot of inhibition (In %) vs. concentration (in μM).[46,47] The free radical scavenging kinetics for standard antioxidant viz. ascorbic acid and the test compounds were calculated using the following formula:

$$\text{DPPH scavenging effect } [\%] =$$
$$[(A_{\text{control}} - A_{\text{sample}})/A_{\text{control}}] \times 100$$

The biological activities of the ligands were examined in terms of DPPH radical scavenging activities where the count fraction causing 50% inhibition of DPPH is called IC_{50}.[49,50]

Cyclovoltammetry

Cyclic voltammograms were recorded of test compounds dissolved in DMSO. Bioanalytical System BASi EPSILON Model instrument with X-Y recorder was applied with a three-electrode framework consisting of a glassy carbon working anode, $Ag^+/AgCl$ as reference electrode, a platinum wire as auxiliary electrode in 0.1 M Et_4NClO_4 as supporting electrode. Ferrocene served as internal standard.[27] The direction of feed potential was from anode to cathode.

Acknowledgements

Author Contribution Statement

B. B. prepared the compounds and wrote the article. I. S. N., T. A. K. and J. J. carried out the antiparasitic assays. A. S. and P. S. S. carried out the antioxidant assay and the cyclovoltammetry experiments. W. S. K., K. A., K. E. and R. S. provided the material, supervised the work and proofread the article.

References

[1] I. Al Nasr, F. Ahmed, F. Pullishery, S. El-Ashram, V. V. Ramaiah,'Toxoplasmosis and anti-toxoplasma effects of medicinal plant extracts-a mini review', *Asian Pac. J. Trop. Med.* **2016**, *9*, 730–734.

[2] A. K. Mitra, A. R. Mason, 'Neglected tropical diseases: epidemiology and global burden', *Trop. Med. Infect. Dis.* **2017**, *2*, 36.

[3] I. Al Nasr, J. Jentzsch, I. Winter, R. Schobert, K. Ersfeld, W. S. Koko, A. A H. Mujawah, T. A. Khan, B. Biersack, 'Antiparasitic activities of new lawsone Mannich bases', *Arch. Pharm. Chem. Life Sci.* **2019**, *352*, e1900128.

[4] C. Burri, 'Sleeping sickness at the crossroads', *Trop. Med. Infect. Dis.* **2020**, *5*, 57.

[5] E. A. Dickie, F. Giordani, M. K. Gould, P. Mäser, C. Burri, J. C. Mottram, S. P. S. Rao, M. P. Barrett, 'New drugs for human African trypanosomiasis: a twenty first century success story', *Trop. Med. Infect. Dis.* **2020**, *5*, 29.

[6] H. P. de Koning, 'The drugs of sleeping sickness: their mechanisms of action and resistance, and a brief history', *Trop. Med. Infect. Dis.* **2020**, *5*, 14.

[7] A. Selvapandiyan, S. L. Croft, S. Rijal, H. L. Nakhasi, N. K. Ganguly, 'Innovations for the elimination and control of visceral leishmaniasis', *PLoS Negl. Trop. Dis.* **2019**, *13*, e0007616.

[8] http://www.who.int/mediacentre/factsheets/fs375/en/; Accessed November 12, **2020**.

[9] K. van Bocxlaer, D. Caridha, C. Black, B. Vesely, S. Leed, R. J. Sciotti, G.-J. Wijnant, V. Yardley, S. Braillard, C. E. Mowbray, J.-R. Ioset, S. L. Croft, 'Novel benzoxaborazole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis', *IJP: Drugs Drug Resist.* **2019**, *11*, 129–138.

[10] I. Bennis, L. Belaid, V. de Brouwere, H. Filali, H. Sahibi, M. Boelart, 'The mosquitoes that destroy your face. Social impact of cutaneous leishmaniasis in south-eastern Morocco', *PLoS One* **2017**, *12*, e0189906.

[11] M. Kassi, A. Afghan, R. Rehman, P. M. Kasi, 'Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan', *PLoS Negl. Trop. Dis.* **2008**, *2*, e259.

[12] S. G. Thacker, I. L. McWilliams, B. Bonnet, L. Halie, S. Beaucage, S. Rachuri, R. Dey, R. Duncan, F. Modabber, S. Robinson, G. Bilbe, B. Arana, D. Verthely, 'CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis', *PLoS Negl. Trop. Dis.* **2020**, *14*, e0008050.

[13] R. K. Kesharwani, K. Misra, D. B. Singh, 'Perspectives and challenges of tropical medicinal herbs and modern drug discovery in the current scenario', *Asian Pac. J. Trop. Med.* **2019**, *12*, 1–7.

[14] R. Pradhan, P. Dandawate, A. Vyas, S. Padhye, B. Biersack, R. Schobert, A. Ahmad, F. H. Sarkar, 'From body art to anticancer activities: perspectives on medicinal properties of henna', *Curr. Drug Targets* **2012**, *13*, 1777–1798.

[15] A. V. Pinto, S. L. de Castro, 'The trypanocidal activity of naphthoquinones: a review', *Molecules* **2009**, *14*, 4570–4590.

[16] A. S. Borade, B. N. Kale, R. V. Shete, 'A phytopharmacological review of *Lawsonia inermis* (Linn.)', *Int. J. Pharm. Life Sci.* **2011**, *2*, 536–541.

[17] R. Inagaki, M. Ninomiya, K. Tanaka, M. Koketsu, 'Synthesis, characterization, and antileukemic properties of naphthoquinone derivatives of lawsone', *ChemMedChem* **2015**, *10*, 1413–1423.

[18] C. P. V. Freire, S. B. Ferreira, N. S. M. de Oliveira, A. B. J. Matsuura, I. L. Gama, F. C. da Silva, M. C. B. de Souza, E. S. Lima, V. F. Ferreira, 'Synthesis and biological evaluation of substituted α- and β-2,3-dihydrofuran naphthoquinones as potent anticandidal agents', *MedChemComm* **2010**, *1*, 229–232.

[19] A. Sharma, I. O. Santos, P. Gaur, V. F. Ferreira, C. R. S. Garcia, D. R. da Rocha, 'Addition of thiols to *o*-quinone methide: new 2-hydroxy-3-phenylsulfanylmethyl[1,4]naphthoquinones and their activity against the human malaria parasite *Plasmodium falciparum* (3D7)', *Eur. J. Med. Chem.* **2013**, *59*, 48–53.

[20] M. L. Bolognesi, F. Lizzi, R. Perozzo, R. Brun, A. Cavalli, 'Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity', *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2272–2276.

[21] R. S. F. Silva, E. M. Costa, Ú. L. T. Trindade, D. V. Texeira, M. C. F. R. Pinto, G. L. Santos, V. R. S. Malta, C. A. de Simone, A. V. Pinto, S. L. de Castro, 'Synthesis of naphthofuranquinones with activity against *Trypanosoma cruzi*', *Eur. J. Med. Chem.* **2006**, *41*, 526–530.

[22] A. V. Pinto, C. N. Pinto, M. C. F. R. Pinto, R. S. Rita, C. A. Pezzella, S. L. de Castro, 'Trypanocidal activity of synthetic heterocyclic derivatives of active quinones from *Tabebuia* sp', *Arzneim.-Forsch.* **1997**, *47*, 74–79.

[23] A. Baramee, A. Coppin, M. Mortuaire, L. Pelinski, S. Tomavo, J. Brocard, 'Synthesis and *In Vitro* activities of ferrocenic aminohydroxynaphthoquinones against *Toxoplasma gondii* and *Plasmodium falciparum*', *Bioorg. Med. Chem.* **2006**, *14*, 1294–1302.

[24] K. Mahal, A. Ahmad, F. Schmitt, J. Lockhauserbäumer, K. Starz, R. Pradhan, S. Padhye, F. H. Sarkar, W. S. Koko, R. Schobert, K. Ersfeld, B. Biersack,'Improved anticancer and antiparasitic activity of new lawsone Mannich bases', *Eur. J. Med. Chem.* **2017**, *126*, 421–431.

[25] J. Jentzsch, W. S. Koko, I. S. Al Nasr, T. A. Khan, R. Schobert, K. Ersfeld, B. Biersack, 'New antiparasitic bis-naphthoquinone derivatives', *Chem. Biodiversity* **2020**, *17*, e1900597.

[26] I. V. Magedov, A. S. Kireev, A. R. Jenkins, N. M. Evdokimov, D. T. Lima, P. Tongwa, J. Altig, W. F. A. Steelant, S. van Slambrouck, M. Y. Antipin, A. Kornienko, 'Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4*H*-Pyrano-[2,3-*b*]naphthoquinones with anticancer activity', *Bioorg. Med. Chem. Lett.* **2012**, *22*, 5195–5198.

[27] M. Gold, Y. Mujahid, K. Ahmed, H. Kostrhunova, J. Kasparkova, V. Brabec, B. Biersack, R. Schobert, 'A new 4-(pyridinyl)-4H-benzo[g]chromene-5,10-dione ruthenium(II) complex inducing senescence in 518 A2 melanoma cells', *J. Biol. Inorg. Chem.* **2019**, *24*, 647–657.

[28] C. Wang, P. Wu, X.-L. Shen, X.-Y. Wei, Z.-H. Jiang, 'Synthesis, cytotoxic activity and drug combination study of tertiary amine derivatives of 2'-4'-dihydroxyl-'-methoxyl-3',5'-dimethylchalcone', *RSC Adv.* **2017**, *7*, 48031–48038.

[29] I. Winter, J. Lockhauserbäumer, G. Lallinger-Kube, R. Schobert, K. Ersfeld, B. Biersack, 'Anti-trypanosomal activity of cationic *N*-heterocyclic carbene gold(I) complexes', *Mol. Biochem. Parasitol.* **2017**, *214*, 112–120.

[30] S. B. Nimse, D. Pal, 'Free radicals, natural antioxidants, and their reaction mechanisms', *RSC Adv.* **2015**, *5*, 27986–28006.

[31] V. Lobo, A. Patil, A. Pathak, N. Chandra, 'Free radicals, antioxidants and functional foods: impact on human health', *Pharmacogn. Rev.* **2010**, *4*, 118–126.

[32] J. Jayabharati, V. Thanikachalam, K. Jayamoorthy, 'Antioxidant benzimidazole bind bovine serum albumin', *J. Photochem. Photobiol. B* **2012**, *115*, 85–92.

[33] S. Rane, K. Ahmed, S. Salunke-Gawali, S. B. Zaware, D. Srinivas, R. Gonade, M. Bhadbhade, 'Vitamin K$_3$ family members-part II: single crystal X-ray structures, temperature-induced packing polymorphism, magneto-structural correlations and probable anti-oncogenic candidature', *J. Mol. Struct.* **2008**, *892*, 74–83.

[34] A. V. Todkary, R. Dalvi, S. Salunke-Gawali, J. Linares, F. Varret, J. Marrot, J. V. Yakhmi, M. Bhadbhade, D. Srinivas, S. Y. Rane, 'SOM assembly of hydroxynaphthoquinone and its oxime: polymorphic X-ray structures and EPR studies', *Spectrochim. Acta Part A* **2006**, *63*, 130–138.

[35] P. Chaudhuri, C. N. Verani, E. Bill, E. Bothe, T. Weihermüller, K. Wieghardt, 'Electronic structure of bis(*o*-iminobenzosemiquinato)metal complexes (Cu, Ni, Pd). The art of establishing physical oxidation states in transition-metal complexes containing radical ligands', *J. Am. Chem. Soc.* **2001**, *123*, 2213–2223.

[36] M. Sorai, D. N. Hendrickson, 'Phase transitions arising from intramolecular electron-transfer in mixed-valence complexes', *Pure Appl. Chem.* **1991**, *63*, 1503–1510.

[37] R. Carrasco, J. Cano, X. Ottenwalder, A. Aukauloo, Y. Journaux, R. Ruiz-García, 'Molecular and electronic structure of square-planar nickel(II), nickel(III) and nickel(III) π-cation radical complexes with a tetradentate *o*-phenylenedioxamidate redox-active ligand', *Dalton Trans.* **2005**, *15*, 2527–2538.

[38] C. R. Hess, T. Weyhermüller, E. Bill, K. Wieghardt, 'Influence of the redox active ligand on the reactivity and electronic structure of a series of Fe(TIM) complexes', *Inorg. Chem.* **2010**, *49*, 5686–5700.

[39] K.-M. Choi, J. Gang, J. Yun, 'Anti-*Toxoplasma gondii* RH strain activity of herbal extracts used in traditional medicine', *Int. J. Antimicrob. Agents* **2008**, *32*, 360–362.

[40] E. Calvo-Álvarez, N. A. Guerrero, R. Álvarez-Velilla, C. F. Prada, J. M. Requena, C. Punzón, M. Á. Llamas, F. J. Arévalo, L. Rivas, M. Fresno, Y. Pérez-Pertejo, R. Balana-Fouce, R. M. Requera, 'Appraisal of a *Leishmania major* strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis', *PLOS Negl. Trop. Dis.* **2012**, *6*, e1927.

[41] I. Al Nasr, 'In vitro anti-leishmanial assessment of some medicinal plants collected from Al Qassim, Saudi Arabia', *Acta Parasitol.* **2020**, *65*, 696–703.

[42] E. Wirtz, S. Leal, C. Ochatt, G. A. Cross, 'A tightly regulated inducible expression system for conditional gene knock-

outs and dominant-negative genetics in Trypanosoma brucei', *Mol. Biochem. Parasitol.* **1999**, *99*, 89–101.

[43] R. S. Twigg, 'Oxidation-reduction aspects of resazurin', *Nature* **1945**, *155*, 401–402.

[44] J. Brinkley, 'Safety and performance development in LSC cocktails', *Am. Biotechnol. Lab.* **1993**, *11*, 48.

[45] S. A. Ahmed, R. M. Gogal Jr., J. E. Walsh, 'A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay', *J. Immunol. Methods* **1994**, *170*, 211–224.

[46] S. Al-Nasiry, N. Geusens, M. Hanssens, C. Luyten, R. Pijnenborg, ,The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells', *Hum. Rep.* **2007**, *22*, 1304–1309.

[47] W. Koko, J. Jentzsch, H. Kali, R. Schobert, K. Ersfeld, I. Al Nasr, T. Khan, B. Biersack, 'Evaluation of the antiparasitic activities of imidazol-2-ylidene-gold(I) complexes', *Arch. Pharm. Chem. Life Sci.* **2020**, *353*, e1900363.

[48] W. S. Koko, M. A. Mesaik, S. Yousaif, M. Galal, M. I. Choudhary, 'In vitro immunomodulating properties of selected Sudanese medicinal plants', *J. Ethnopharmacol.* **2008**, *118*, 26–34.

[49] T. Shimamura, Y. Sumikura, T. Yamazaki, A. Tada, T. Kashiwagi, H. Ishikawa, T. Matsui, N. Sugimoto, 'Applicability of the DPPH assay for evaluating the antioxidant capacity of food additives-inter-laboratory evaluation study', *Jpn. Soc. Anal. Chem.* **2014**, *30*, 717–721.

[50] E. J. Garcia, T. L. C. Oldoni, S. M. de Alencar, A. Reis, A. D. Loguercio, R. H. M. Grande, 'Antioxidant activity by DPPH assay of potential solutions to be applied on bleached teeth', *Braz. Dent. J.* **2012**, *23*, 22–27.